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Abstract 
Uhlen et al. (Reports, 18 august 2017) published an open-access resource with cancer-specific 
marker genes that are prognostic for patient survival in seventeen different types of cancer. 
However, their data analysis workflow is prone to the accumulation of false positives. A more 
reliable workflow with flexible Cox proportional hazards models employed on the same data 
highlights three distinct problems with such large-scale, publicly available omics datasets from 
observational studies today: (i) re-analysis results can not necessarily be taken forward by others, 
highlighting a need to cross-check important analyses with high impact outcomes; (ii) current 
methods are not necessarily optimal for the re-analysis of such data, indicating an urgent need to 
develop more suitable methods; and (iii) the limited availability of potential confounders in public 
metadata renders it very difficult (if not impossible) to adequately prioritize clinically relevant 
genes, which should prompt an in-depth discussion on how such information could be made more 
readily available while respecting privacy and ethics concerns. 
--------------------------------------------------------------------------------------------------------------------- 
Uhlen et al. (1 )  published an open-access resource with cancer-specific prognostic marker 
genes based on a genome-wide transcriptome analysis of The Cancer Genome Atlas (TCGA) 
data compendium. For this study, they constructed more than 100 million Kaplan-Meier survival 
plots (Figure 1A), and corresponding significance levels were used to establish sets of favorable 
and unfavorable prognostic marker genes in different types of cancer. These markers were then 
communicated via the Human Pathology Atlas web resource (HPA). However, their data 
analysis workflow shows three shortcomings concerning specificity: (i) binarization of count 
data, (ii) multiple testing correction issues at two distinct levels, and (iii) ignoring baseline 
confounders. We here investigate the consequences and severity of these shortcomings, present 
more appropriate solutions for these problems, compare the results of our updated workflow to 
those of the original workflow and highlight challenges to prioritize clinically relevant genes from 
omics data of large-scale observational studies.  
 
Binarization of count data 
To create the 100 million Kaplan-Meier plots on which the study is based, patients are classified 
into two groups based on their gene expression (GE) level: above or below a certain cut-off value. 
This binarization leads to a huge loss of information, as information-rich GE count data are 
translated into the equivalent of an on/off state.  
 
Multiple testing issues 
Of greater concern are the multiple testing issues, which occur at the level of the cut-off for 
binarization, and at the level of gene prioritization. Both are discussed below. 
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For the binarization, the criterion to bin GE levels was derived by exploring all possible GE cut-
off values for each gene, thus generating hundreds of Kaplan-Meier plots per gene. Based on 
these plots, the cut-off with the best separation in survival between groups (i.e., the lowest p-
value) was chosen (Figure 1B). The strategy thus de facto performs a large number of tests per 
gene, which requires correction for multiple testing. Yet such a correction was not performed and 
is moreover not trivial given the overall data analysis workflow and study design.  As a result, 
there is a substantially increased risk for false positive marker selection. This can already be 
expected from the huge number of genes that were communicated as marker genes in e.g. the 
TCGA breast cancer dataset, with 847 genes having a p-value below 0.001 and 7749 genes with 
a p-value below 0.05, out of 17040 genes. 
 
To demonstrate the repercussions of this data dredging strategy, we randomly shuffled the 
survival times from the TCGA database. This breaks the original association between the survival 
data and the GE profiles of the patients as well as the association between the survival data and 
baseline confounders. By applying the original binarization strategy adopted by Uhlen et al. (1) to 
this mock dataset, we obtained 320 genes with p-values below p<0.001 and 6410 genes with 
p<0.05, while a valid statistical procedure is expected to return around 17 (0.1% of 17040) and 852 
genes (5% of 17040) under the null, respectively. Moreover, we show that the Uhlen et al. (1) 
method distorts the entire p-value distribution under the null hypothesis of no association (see 
Supplementary Materials Section 2.2.1). 
 
When combining the results of all genes, a classical multiple testing problem arises. Indeed, 
thousands of genes are being tested as potential markers and multiple testing must be addressed. 
Again, no such correction is adopted in the analysis of Uhlen et al. (1). 
 
Taken together, these two multiple testing problems, occurring at distinct two levels, create an 
intractable overall multiple testing problem, which inevitably leads to highly inflated false 
positive rates in the original Uhlen et al. analysis (1).  
 
Confounders 
The third and final issue lies in the presence of confounders, which are not taken into account in 
the analysis of Uhlen et al. (1). For instance, in the TCGA breast cancer dataset, age has an 
extremely significant contribution to the hazard ratio (P = 5.3E-11, Figure 1C). As such, an 
analysis ignoring baseline confounders cannot correctly assess the impact of GE on survival 
(Figure 1 panels D - F).  
 
An elegant solution to the three issues of the Uhlen analysis (1) is to build upon the semi-
parametric Cox proportional hazards (CPH) framework (2) (see Supplementary Materials for 
details). Indeed, this allows us to model survival data using both categorical (e.g. gender) and 
quantitative predictors (e.g. GE, age, …), thus avoiding issues regarding the wasteful 
binarization of GE data and measured baseline confounders. For gene IL27RA, for instance, a 
decrease in hazard can be observed as GE levels increase (Figure 1F). Moreover, with the CPH 
approach we can assess the association between the expression of each gene and survival with a 
single test, in turn enabling the use of conventional false discovery rate (FDR) procedures to 






Analysis with the semi-parametric Cox proportional Hazards model 
We illustrate the CPH framework on the TCGA breast cancer (BRCA) and liver cancer 
(LIHC) datasets. Note that all the results can be found on our companion GitHub page, 
https://github.com/statOmics/pitfallsOfHumanPathologyAtlas. We include a spline term for 
gene expression and for the available confounders (age in the BRCA analysis and age and 
body mass index in the LIHC analysis, see Supplementary Materials for details). For both 
datasets, we observe a clear discrepancy between the results provided by Uhlen et al. (1) 
and those of our improved workflow (Supplementary Tables 1-4). 
 
For the BRCA dataset, including the confounder age strongly impacts the ranking of the genes, 
with many of the top genes originally identified moving to a substantially lower ranking in our 
analysis, and vice versa. Interestingly, several of the markers exclusively identified as high-ranking 
in our analysis are well-known breast cancer markers, for instance, MMP13 and RGL3.  This 
emphasizes the importance of correcting for confounders. Uhlen et al. (1) report 847 genes to be 
significantly associated with survival (uncorrected p-value < 0.001). Strikingly, no genes were 
found to be significantly associated with survival upon correcting for the confounder age and 
multiple testing (5% FDR significance level). 
 
For the LIHC analysis, the impact on the ranking of the genes is comparatively small, as most 
genes in our top 10 list are among the 50 highest ranking genes in the original publication. As 
expected, the adjusted p-values obtained by our workflow are several orders of magnitude larger 
than those in the original publication, given that we appropriately correct for multiple testing. For 
the LIHC analysis, we identified 2812 genes that are significantly associated with survival (5% 
FDR significance level), markedly less than in the original publication (3501 genes with 
uncorrected p < 0.001).  
 
Note, however, that the distribution of test statistics and p-values of all genes in our CPH 
approach indicates failure of the theoretical null distribution of the test statistic for both case 
studies (see Supplementary Materials). Efron (4) argued that this can be due to 4 reasons: failed 
mathematical assumptions, correlation across genes, correlation across patients, and unobserved 
confounders in observational studies. When we use his local false discovery rate approach, which 
exploits the massive parallel data structure to empirically estimate the null distribution, no 
significant association between gene expression and survival remains in both case studies. We 
also further examined why the theoretical null distribution failed in our context, and could show 
that the semi-parametric Cox model suffered from all of the above four reasons in both case 
studies (see Supplementary Materials). However, when replacing the spline-based likelihood 
ratio test (LRT) with an LRT for a linear and quadratic GE-effect, we no longer observed failure 
of the null due to mathematical assumptions. Nevertheless, the null of this quadratic CPH model 
still suffers from unobserved confounders (BRCA and LIHC) and from correlation between 
genes (LIHC). The former, however, could not be addressed using the publicly available baseline 
confounders. This indicates the challenges of prioritizing clinically relevant genes from large 
scale observational studies. 
 
Conclusion 
The advent of large open-access, knowledge-based efforts, such as TCGA, opens the way for 
high-throughput statistical (re-)analyses to facilitate novel experiments, e.g. through the 
construction of prioritized gene sets. However, our assessment highlights that there are at least 
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three distinct problems with such datasets today: (i) re-analysis results can not necessarily be 
taken forward by others; (ii) current methods are not necessarily optimal for the re-analysis of 
such data; and (iii) the limited availability of potential confounders in the public metadata renders 
it very difficult (if not impossible) to adequately prioritize clinically relevant genes. Possible 
solutions to these problems are to (i) involve statisticians in such large-scale re-analyses; (ii) to 
foster further developments in causal inference, survival analysis and multiple testing for large-
scale omics analyses from observational studies; and (iii) to develop ways to make potential 
confounders available for such large-scale, open-access data compendia while adhering to 






Figure 1: A) Kaplan-Meier plot for breast cancer patients stratified by the expression of the IL27RA 
gene (Uhlen et al., 2017 (1)). Patients with an IL27RA expression higher than the “optimal cut-off” 
display a higher survival rate. B) Data dredging: Distribution of log-rank p-values against the RNA 
expression of the IL27RA gene with different expression cut-offs on the BRCA dataset. A minimal p-
value of 2.12E-06 is found at an expression threshold of 7.504. C) A Cox model for age only 
demonstrating the contribution of this confounder to the proportional hazard. Clearly, this hazard 
increases for increasing age. The flags at the bottom indicate observations. D) Baseline confounders: 
Confounders, such as a patient’s age, affect both gene expression and survival. As a consequence, the 
effect of both arrows B and C could be misconstrued as a direct effect of gene expression. E) A Cox 
model for the IL27RA gene with its contribution to the proportional hazard as a function of its log 
expression. The flags at the bottom indicate observations. F) A Cox model for IL27RA corrected for 
age effects. As compared to figure 1E, the contribution of the IL27RA to the hazard has dropped for 
lower expression values and the p-value of the test is less significant (more than ten times higher). The 
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Pitfalls in re-analysis of observational omics studies:  
a post-mortem of the human pathology atlas. 
Supplementary material 
 
This document serves as supplementary material for the technical comment on “A pathology atlas 
of the human cancer transcriptome” by Uhlen et al., 2017 (1), describing the rationale and 
methodology of each step in our revised workflow, supplemented with R-code on our GitHub 
companion page: https://github.com/statOmics/pitfallsOfHumanPathologyAtlas. Analyses will 
be limited to the breast cancer (BRCA) and liver cancer (LIHC) datasets supplied by The Cancer 
Genome Atlas (TCGA) project via the Genomic Data Commons (GDC) data portal, but the 
procedures for other datasets in the TCGA repository are analogous. 
 
1. Reconstruction of the original Kaplan-Meier analysis 
 
First, we reconstruct the Kaplan-Meier plots from the survival analysis of the original publication 
by Uhlen et al. (1). There, patients were divided in two groups based on the expression value of 
a certain gene, i.e. above or below a certain cut-off value. To gain insight in the rationale of their 
methodology, we reconstruct these plots for the BRCA dataset (Figure S1). For concordance with 
the original publication, our analysis uses FPKM (fragments per kilobase million) expression 
values. Here, we only show the Kaplan-Meier curves of the top two favorable and unfavorable 
prognostic marker genes.  
p = 2.01E-06 
Figure S1: Example of Kaplan-Meier plots for two of the most significant favorable markers (top 
row) and unfavorable markers (bottom row) in the TCGA breast cancer dataset. The expression of 
the selected genes has a strongly significant association with survival based on the Kaplan-Meier analysis. 
The p-values are indicated in the plot. Note that these values might slightly deviate from those in the 
original publication, due to updates in the TCGA data compendium. Black and red lines show the survival 
of patients with gene expression values higher and lower than the optimal cut-off value, respectively. 




































p = 2.58E-08 p = 2.18E-07 
p = 5.55E-07 
ARID5A 
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The source code for creating these plots is available on our companion GitHub page 
/BRCA/originalBRCA.Rmd. Note, that the resulting p-values and plots might not be identical to 
those published by Uhlen et al.  (2017), due to regular updates of the TCGA data compendium. 
 
2. Shortcomings of the original Kaplan-Meier analysis 
 
We report three shortcomings of the original Kaplan-Meier analysis concerning specificity of the 
reported prognostic marker genes: (i) binarization of count data, (ii) multiple testing correction 
issues at two distinct levels, and (iii) ignoring baseline confounders. Here, we will discuss 
each of these shortcomings in depth. We first show where the existing issues cause problems in 
the analysis, which we subsequently prove using simulated data. Next, we proceed to correct for 
these issues using appropriate methods in a revised and more reliable workflow. 
 
2.1. Binarization of count data 
 
To regenerate the original Kaplan-Meier plots, patients are classified into two groups based on 
their gene expression level: above or below a certain cut-off value. This binarization leads to a 
huge loss of information, as information-rich gene expression count data are translated into the 
equivalent of an on/off state. This wasteful binarization of the expression values, however, can be 
avoided altogether by modeling survival using semi-parametric Cox proportional hazards models 
(2), which we will discuss in Section 3. 
 
2.2. Multiple testing problems and p-hacking 
 
The cut-offs on the gene expression values to generate Figure S1 were obtained from the 
supplementary tables of the original publication. In order to achieve the largest possible 
distinction between the survival of both patient groups, these cut-offs were generated with a data 
dredging strategy. More explicitly, the dataset was exhaustively searched for gene-expression cut-
offs (i.e. prior to the actual data analysis) which would finally lead to the smallest possible p-
value for each gene. The source code for generating these plots for the breast cancer dataset is 
available on our companion GitHub page /BRCA/originalBRCA.Rmd. The plot for the IL27RA 
gene in the BRCA dataset is shown in Figure S2. 
 
This strategy thus de facto performs a large number of tests per gene, which requires correction 
for multiple testing. Yet, such a correction was not performed and is moreover not trivial given 
the overall data analysis workflow and study design.  As a result, there is a substantially increased 
risk for false positive marker selection. This can already be expected from the huge number of 












Figure S2: Selecting a cut-off gene expression 
value for the gene IL27RA as described by 
Uhlen et al. The cut-off value is selected by 
evaluating all gene expression (FPKM) values 
from the 20th to the 80th percentile and by 
subsequently selecting the value that achieves the 
most significant difference in the survival of the 
resulting groups. Significance is expressed as the 
lowest Kaplan-Meier p-value (highest -log10 p-
value). Note that the calculated cut-off values 
might not be identical to those supplied by Uhlen 





genes having a p-value below 0.001 and 7749 genes with a p-value below 0.05, out of 17040 
candidate genes. For the LIHC dataset, the original publication even suggested as much as 3501 
genes with a p-value below 0.001 and 10632 genes with a p-value below 0.05, out of 16397 
candidate genes.   
 
Below, we will make use of simulated data to demonstrate the repercussions of this data dredging 
strategy. 
 
2.2.1  Mock analysis 
 
To demonstrate the repercussions of the data dredging strategy, we randomly shuffled the TCGA 
survival data (companion GitHub page /BRCA/originalBRCA_problems.Rmd). This breaks the 
original association between the survival data and the GE profiles as well as the association 
between the survival data and baseline confounders. Hence, this mock dataset does not contain 
marker genes that are associated with survival. By applying the original binarization strategy 
adopted by Uhlen et al. (1) to this mock dataset, however, we obtained 320 genes with p-values 
below p<0.001 and 6410 genes with p<0.05, while a valid statistical procedure is expected to return 
17 (0.1% of 17040) and 852 genes (5% of 17040) under the null, respectively. In Figure S3, we 
show Kaplan-Meier plots that were generated with Uhlen et al. strategy for the top genes of the 
mock analysis. 
 
Figure S4 (left panel) shows that the distribution of the p-values is unnaturally skewed towards 
small values; strikingly, the largest p-value that was obtained for this mock dataset, which again 
does not contain markers, was p = 0.65. In principle, valid p-values under the null hypothesis 
should be uniformly distributed over the entire [0,1] interval. As such, it becomes clear that the 
results reported by the Uhlen et al. method are meaningless. 
 
Intriguingly, the distribution of the p-values in the original Kaplan-Meier analysis for the BRCA 
dataset are equally skewed towards small values (Figure S4, right panel). For a valid statistical 
procedure, one would expect a uniform distribution of p-values in the absence of prognostic 
marker genes. The presence of a number of genes that are truly associated with survival would 
result in an inflation of p-values close to zero, however, the larger p-values are supposed to be 
uniformly distributed. The observed pattern clearly demonstrates that the resulting p-values of the 
Uhlen et al. analysis are strongly biased towards small values as a consequence of the data 
dredging strategy for determining the binary gene expression cut-off values. 

















Figure S3: Example of Kaplan-Meier plots for two of the most significant genes in the mock analysis. 
With the cut-off-based strategy that was adopted in the original publication of Uhlen et al. (2017), p-values 
as small as 2.62E-07 were obtained in the mock dataset for which no significant association between gene 
expression and survival occurs. 





As a third shortcoming, the original analysis ignores baseline confounders. Confounders disrupt 
the causal interpretation of the dependent and explanatory variable(s). Since factors such as the 
age of a patient already have significant impact on survival and are also influencing the expression 
of certain genes, the analysis should be corrected for such confounders when assessing the impact 
of gene expression on survival. The earlier proposed Cox proportional hazards model also allows 
to include confounders and shall hence be used for a more reliable survival analysis, as discussed 
in Section 3. 
 
3. Cox proportional hazards models 
 
We propose the use of the semi-parametric Cox proportional hazards  (CPH) models for revisiting 
the original analysis of the TCGA datasets (2). First, CPH models circumvent binarizing gene 
expression values, as they allow for the modeling of quantitative variables, directly. Second, 
treating the gene expression value as a quantitative variable removes the need for exhaustively 
searching the dataset for artificial gene expression cut-off values. This greatly eases the 
downstream multiple testing correction. Indeed, we now only need to correct for the fact that 
multiple genes were assessed simultaneously, for instance, by adopting the false discovery rate 
procedure as described by Benjamini and Hochberg (3).  Finally, CPH models allow for 
confounders to be included as covariates. Hence, the analysis will be more reliable with respect 
to finding marker genes that are truly associated with the cancer phenotype. 
 
The Cox hazard function can be interpreted as the risk of undergoing a certain event (in this case, 
death) at time t: 
 




Figure S4: Histogram of the distribution of the Kaplan-Meier p-values in the mock analysis. Left 
panel; As a consequence of the p-hacking strategy, no values larger than p = 0.65 are obtained, even in the 
analysis of the mock dataset. While under the null hypothesis the p-values of a valid statistical inference 
procedure are expected to be uniformly distributed over the [0,1] interval (i.e. no association between any 
of the genes and survival), their observed distribution is strongly skewed towards small values. Right panel; 
When displaying the p-values of the original publication for the BRCA dataset, we can see that they are 
equally skewed towards small values. This clearly demonstrates that the resulting p-values of the original 
analysis are strongly biased towards small values as a consequence of the p-hacking strategy, which implies 
an accumulation of false positive markers. 













In this equation, 
• h0(t) is the baseline hazard (which can vary throughout time) 
• X is a set of covariates each with an effect size β. In this CPH model X captures the 
association of the expression for the gene in question. To correct for confounders, 
additional covariates such as age or body mass index (BMI) can be incorporated. 
 
In order to achieve a good fit and to capture potential nonlinear associations, we use a spline 
function. Spline functions expand a quantitative predictor (z) in a set of basis functions: e.g. x1 … 
xk: 
𝑥1(𝑧)  =  𝑃1(𝑧),     𝑧0  ≤   𝑧  ≤   𝑧1 
𝑥2(𝑧)  =  𝑃2(𝑧),     𝑧1  ≤   𝑧  ≤   𝑧2 
… 
𝑥𝑘(𝑧)  =  𝑃𝑘(𝑧),     𝑧𝑘−1  ≤   𝑧  ≤   𝑧𝑘 
 
In this equation, 
• 𝑃𝑖(𝑧) are different polynomials for gene expression value z 
• The given k+1 points are referred to as knots, these can be evenly spaced throughout 
the parameter space like in the pspline-function of the Survival R package (4). Due 
to the nature of the observational study, however, the predictor data are much denser 
in intervals in the middle than intervals at the boundaries. To avoid overfitting in the 
boundary regions the original pspline-function is modified to a user-defined spline 
function referred to as ‘qspline’, where knots are set at evenly spaced quantiles. This 
made the fit more robust against outliers and modelled the middle of the predictor space 
with increased detail. 
 
Note; for all analyses that are not reconstructions of the work by Uhlen et al. (1), we work with 
log-transformed counts-per-million as gene expression values. As the expression data is dissected 
for each gene and not across all genes, FPKM expression values do not provide added value to 
the analysis. All analyses related to the CPH models can be retrieved on our compagnion GitHub 
repository, i.e. from scripts /BRCA/revisitedBRCA.Rmd and /LIHC/revisitedLIHC.Rmd for the 
breast cancer and liver cancer datasets, respectively. 
 
4. Deviations from the theoretical null distribution 
 
We applied CPH models to quantify the strength of the association between the expression of 
each gene in the dataset and patient survival, after correcting for patient specific confounders. In 
brief, a likelihood ratio test between two models was used, comparing the fit between (i) a CPH 
model that models a patient’s survival based only on this patient’s age (BRCA dataset) or age and 
BMI (LIHC dataset), and (ii) a CPH model that models survival based on the confounders and 
gene expression values. Note, that we use splines to model the association with gene expression 
and the confounder(s).  
 
In transcriptomics data analysis, it is commonly assumed that most genes in the dataset are null 
genes, i.e. most genes are not associated with survival. Under the assumption of only null genes, 
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the distribution of the p-values, that quantify the significance of the association between gene 
expression and survival, are uniformly distributed over the [0,1] interval. The presence of a 
relatively small number of genes that are truly associated with survival will result in an inflation 
of p-values close to zero. As shown in the right panel of Figure S4, the data dredging strategy that 
was adopted in the original publication leads to a p-value distribution that is strongly skewed 
towards small values. However, when taking a closer look to the p-values derived from our 
proposed workflow for BRCA dataset, an almost linear decrease over the entire [0,1] interval is 
observed (Figure S5, left panel). While for the LIHC dataset there seems to be a clear inflation of 
near-zero p-values, a linear decrease in the distribution of p-values in the [0.1, 1] interval can still 
be observed (Figure S5, right panel). 
Such behavior indicates failure of the theoretical null distribution. In this example, one would 
expect the likelihood ratio test statistic to be chi-squared distributed under the null hypothesis, 
with the number of degrees of freedom equal to those of the CPH models (which were set to df = 
4 in our analysis, see scripts /BRCA/revisitedBRCA.Rmd and /LIHC/revisitedLIHC.Rmd) and 
we expect the majority of the genes to follow the null. However, this assumption is clearly not 
met for the majority of the test statistics in our respective workflows (see Figure S6).  
 
BRCA LIHC 
Figure S5: Histogram of the distribution of the p-values for our proposed Cox proportional hazards 
model. Left panel; p-values for the breast cancer datasets. Under the null hypothesis, i.e. when assuming no 
association between any of the genes and survival, a uniform distribution of p-values is expected. When 
association between some of the genes and survival is present, this would result in an inflation of near-zero p-
values. Here, in contrast, the distribution of the p-values seems to decrease almost linearly over the [0,1] 
interval, which suggests a violation of an underlying assumption of the null distribution of the test statistics. 
Right panel; p-values for the liver cancer dataset. While for this dataset there seems to be a clear inflation of 
near-zero p-values, a linear decrease in the distribution of p-values in the [0.1, 1] interval can still be observed. 
chisq chisq 
BRCA LIHC 
Figure S6:  The majority of the test statistics do not follow the theoretical null distribution. Left panel; 
breast cancer dataset. Under the null hypothesis, the test statistics are expected to follow a chi-squared 
distribution with 4 degrees of freedom (red line). However, the test statistics are shifted towards larger 
values, indicating that a massive number of genes are associated with survival or failure of the theoretical 
null jeopardizing reliable inference. Right panel; liver cancer dataset. A similar behavior in the distribution 
of test statistics as in the breast cancer dataset is observed. 
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Efron (5, Chapter 6) describes four reasons why the theoretical null distribution may fail; (I) failed 
mathematical assumptions, (II) correlation across genes, (III) correlation across patients, and (IV) 
unobserved confounders in observational studies. A schematic representation of the data structure 
in our study is depicted in Supplementary Figure S7 and illustrates reasons (II), (III) and (IV).  
 
Efron argues to correct for these issues by estimating the null distribution empirically.  
Particularly, we will make use of the companion ‘locfdr’ package developed by Efron et al. (6). 
As suggested by Efron (5, Chapter  6) for test statistics that follow a chi-squared theoretical null 
distribution, we first convert the p-values obtained from the analysis of the BRCA and LIHC 
datasets, respectively, to z-scores according to, 
 
𝑧𝑖  =    Ф
−1(1 − 𝑝𝑖),     (1) 
 
with pi the original p-value indicating the significance of association between the expression of 
gene i and survival, Ф the cumulative distribution function for the standard normal distribution 
and zi the resulting z-score for gene i. Note, that for this transformation associations between gene 
expression and survival with small p-values all will end up in the right tail of the z-score 
distribution. We now visualize the resulting z-score distributions for the BRCA and LIHC 
datasets, respectively (Figure S8, panels A and B). 
 
Efron (5), further, assumes a mixture distribution for the z-scores, i.e.  
 
𝑓(𝑧) = 𝜋0𝑓0(𝑧) + (1 − 𝜋0)𝑓1(𝑧),     (2) 
 
with 𝑓(𝑧) the mixture distribution of the z-scores, 𝑓0(𝑧) the distribution of the z-scores for the 
genes that are not associated with survival (under 𝐻0) and 𝑓1(𝑧) the distribution of the z-scores 
for the genes that are associated with survival (under 𝐻1) and 𝜋0 the proportion of genes that are 





 ,     (3) 
i.e. the posterior probability that a specific gene with a score z is a null gene (false positive) (7). 





Figure S7: Schematic representation of the data 
structure in this study. The response variable, survival 
time (S), is a vector of length N, with N the number of 
patients in the BRCA or LIHC datasets. There are two 
matrices of explanatory variables. On the top left, we 
have an 𝑀 × 𝑁 matrix of gene expression values, with 
M the number of genes. On the bottom left, we have an 
𝐿 × 𝑁 matrix of confounders, with L the number of 
confounders. Note, that these confounders may be 
measured or unmeasured. The arrows indicate 
dependencies between the different data types. We also 
indicate three of the reasons discussed by Efron (5) for 
failure of the theoretical null; (II) correlation across 
genes, (III) correlation across patients and (IV) 
unmeasured confounders. Cells and columns that are 
separated suggest independent observations, whereas 
concatenated cells suggest dependent or correlated 
observations.   
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number of false positives (null genes) in the set of significant genes, say S, that is returned. In 
fact, the FDR is the expected value of the lfdr of all genes in set S,  
 
FDR = 𝐸𝑆[lfdr].     (4) 
 
He also argues that the use of an lfdr significance level of 0.2 approximately corresponds to an 
FDR significance level of 0.05 in many applications. With his package locfdr (6), 
𝜋0, 𝑓0(𝑧) and 𝑓(𝑧) are estimated empirically by exploiting the massive parallel structure of omics 
data.  
 
For the BRCA dataset, the empirical null distribution of the resulting z-scores is shifted as 
compared to the theoretical standard normal distribution (Δ = 0.656). For the LIHC dataset, the 
resulting z-scores are shifted as well (Δ = 1.163), and the distribution additionally becomes wider 
than the theoretical null (σ = 1.217). As such, it is clear that inference based on the theoretical 
null distribution would lead to erroneous results. If we instead make use of the lfdr approach 
proposed by Efron et al. (6, 7), no significant associations between gene expression and survival 
remain in either case study (lfdr < 0.2).  
 
However, we do observe that the estimated empirical null component densities (blue dashed 
curves in Figure S8, panels A and B) do not seem to fit the observed distribution of z-scores very 
well. In both the BRCA and LIHC datasets, there are clear deviations between the estimated null 
component density and the observed z-score distribution in the left tail of the distribution. The 
deviations in the right tail of the distribution for the LIHC dataset (Figure S8 panel B) are harder 
to interpret, as they may either arise from a suboptimal fit of the empirical null or the presence of 
genes that are truly associated with survival. Note that errors in fitting the null density in the right 
tail are more severe than errors in the left tail from a practical perspective, as genes that are 
associated with survival will all be present in the right tail, given how the z-scores were generated 
(Formula 1). 
 
To further examine why the theoretical null distribution fails for these two datasets, we first omit 
the correction for the baseline confounders (Figure S8, panels C and D). This did not have a 
noteworthy impact on the estimation of the empirical null distribution, suggesting that correcting 
for confounders does not have a strong impact on the estimation of the empirical null. Next, we 
model the association between gene expression and survival with a linear and a quadratic term for 
gene expression (Figure S8, panels E and F), rather than spline term (Figure S8 panels A-D). For 
the BRCA dataset, the empirical null distribution of the resulting z-scores remains shifted as 
compared to the theoretical standard normal distribution (Δ = 0.412) and has additionally become 
wider (σ = 1.151). For the LIHC dataset, the resulting z-scores are also shifted (Δ = 0.930) and 
wider than the theoretical null (σ = 1.456). The imperfect fit of the empirical null to the left tail 




Figure S8: Z-scores for the association between gene expression and survival on the original BRCA 
(left panels) an LIHC (right panels) datasets. The blue dashed curves represent the estimated empirical 
null component densities. The green solid curves represent the fitted mixture density, i.e. a mixture between 
the null genes and marker genes (non-null). Panels A and B; Z-score distributions when modelling gene 
expression with a spline function, while correcting for confounders. For the BRCA dataset, the empirical 
null distribution of the resulting z-scores is shifted as compared to the theoretical standard normal 
distribution (Δ = 0.656). For the LIHC dataset, the resulting z-scores are shifted as well (Δ = 1.163), and the 
distribution additionally becomes wider than the theoretical null (σ = 1.217). Note that the empirical null 






Next, we systematically assess which of four potential reasons is involved in the failure of the 
theoretical null distribution in both our case studies.  
 
The issue of failed mathematical assumptions in our applications would mean that the asymptotic 
chi-squared distribution is invalid for instance due to the violation of the proportional hazards 
assumption or because of the use of penalized regression with splines.  
 
As described by Efron (5), the issue of failed mathematical assumptions is the only type of failure 
that can be addressed via permutations. In the remainder of this section we will exploit 
permutation strategies to generate data under the null hypothesis of no association between gene 
expression and survival under controlled assumptions. So, the analyses displayed below can be 
solely used to identify potential reasons for failure of the null distribution and not to improve the 
analysis as such.  
 
Under the first strategy we randomly permute the gene expression data between patients for each 
gene separately (Figure S9). This breaks the correlation between different genes within patient as 
well as the association with both survival and the confounders. Hence, under this permutation 
strategy, the empirical null distribution can only deviate from the theoretical null distribution if 





Figure S8 (continued): The deviations in the right tail of the distribution for the LIHC dataset (Figure S8 panel 
B) are harder to interpret, as they may either arise from a suboptimal fit of the empirical null or the presence of 
genes that are truly associated with survival. Panels C and D; Z-score distributions when modelling gene 
expression with a spline function, ignoring confounders. As compared to panels A and B, we here did not 
correct the analysis for confounders. This only had a very minor impact on the estimation of the empirical null 
distribution. Panels E and F; Z-score distributions when modelling gene expression with a linear and a 
quadratic term, ignoring confounders. For the BRCA dataset, the empirical null distribution of the resulting 
z-scores remains shifted as compared to the theoretical standard normal distribution (Δ = 0.412) and has 
additionally become wider (σ = 1.151). For the LIHC dataset, the resulting z-scores are also shifted (Δ = 0.930) 
and wider than the theoretical null (σ = 1.456). The imperfect fit of the empirical null to the left tail of the 






Figure S9; First permutation strategy. We 
randomly permute the gene expression data between 
patients, for each gene separately. This breaks the 
correlation between different genes within patient 
(issue II), as well as the association between gene 
expression on the one hand and survival and the 
confounders on the other hand, as indicated by the 
red crosses. Hence, under this permutation strategy, 
the empirical null distribution can only deviate from 
the theoretical null distribution if there is a violation 
of the assumptions of the underlying mathematical 
model (issue I). 
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The empirical null distribution for one permuted dataset where the expression of each gene is 
shuffled independently is depicted in Figure S10. When assessing the association between gene 
expression and survival with a spline-based likelihood ratio test, shifts and deviations in the width 
of the empirical null distribution as compared to the theoretical null remain in the both the 
permuted BRCA and LIHC datasets, suggesting failed mathematical assumptions. By contrast, 
when the analysis is performed with a likelihood ratio test based on a model with a linear and 
quadratic gene expression effect, we no longer observe failure of the null due to mathematical 
assumptions; the estimated empirical null distribution overlaps almost perfectly with the 
theoretical standard normal distribution upon conversion of the p-values in z-scores. 
 
The failure of the mathematical assumptions of the spline-based model may be explained by the 
fact that we adopted penalized estimation and further research is required to efficiently unlock 




As we observed failure of mathematical assumptions for the spline-based model but not for a 
model with linear and quadratic terms for gene expression, we continue exploring the other three 
issues for deviations of the theoretical null distribution for the latter model. 
 
To assess the issue of correlation across genes, we generate data under a second permutation 
strategy (Figure S11). Here we will randomly permute the survival data of the different patients. 
This breaks the association (i) between a patient’s gene expression profile and survival, and (ii) 
between a patient’s confounders (i.e. both observed and unobserved confounders) and survival. 
Note, that the correlation across genes are retained in this scenario, as opposed to the previous 
permutation strategy.  
Figure S10: Z-scores for the association between gene expression and survival on the permuted BRCA 
(left panels) an LIHC (right panels) datasets. The blue dashed curves represent the estimated empirical null 
component densities. The green solid curves represent the fitted mixture density, i.e. a mixture between the 
null genes and marker genes (non-null). The data were permuted according to the first permutation strategy, 
as described in Figure S9. Panels A and B; Z-score distributions when modelling gene expression with a 
spline function, ignoring confounders.  For both permuted datasets, the observed empirical null distribution 
is shifted and narrowed with respect to the theoretical null, suggesting failed mathematical assumptions. 
Panels C and D; Z-score distributions when modelling gene expression with a linear and quadratic 
term, ignoring confounders. With the linear and quadratic term for gene expression, we no longer observe 














Figure S11: Second permutation strategy. We 
randomly permute the patient survival data, as 
indicated by the asterisk in the survival vector. 
We repeat the permutation six times for both the 
BRCA and LIHC datasets so that the conclusions 
are not driven by one specific permutation.  The 
permutation breaks the association (i) between a 
patient’s gene expression profile and survival 
data, and (ii) between a patient’s confounders 
(i.e. both observed and unobserved confounders) 
and survival data. Comparing with the first 
permutation strategy shown in Figure S9, this 
second permutation strategy allows to assess the 
effect of issue II. 







We observe a clear discrepancy between the empirical null distribution in the permuted BRCA 
dataset and the permuted LIHC dataset. For the former, the estimated empirical null distribution 
overlaps almost perfectly with the theoretical standard normal distribution (Δ; [-0.09; 0.08] and  
σ; [0.93; 1.01] for six repeated permutations) with only very minor deviations between the 
empirical null and the observed z-scores. This suggests that for the BRCA dataset that issue II, 
potential correlation across genes, does not cause major problems in the BRCA case study. For 
the LIHC dataset, we observe that the empirical null is shifted as compared to the theoretical null 
(Δ; [-0.08; 0.38] and σ; [0.94; 1.08]) for the six repeated permutations, with some deviations 
between the empirical null and the observed z-scores in the right tail. This suggests issue II is 
one of the underlying problems in the LIHC dataset. 
 
In Figure S8, panels E and F, we showed that for both the BRCA and LIHC case studies the 
empirical null distributions are shifted and widened as compared to the theoretical standard 
normal distribution, when modeling survival as a function of gene expression with a linear and 
a quadratic term. This analysis, however, did not yet correct for the measured confounders. 
Therefore, we here inspect the empirical null distribution for both case studies when we 
additionally include a correction for the available baseline confounders through a spline function 
(age for the BRCA dataset, age and BMI for LIHC dataset). Note, that while we advised against 
modelling gene expression with a spline function of fixed degrees of freedom, modelling the 
confounders with a spline model should not be problematic, as we are not evaluating significance 
of the spline term in the actual inference (with the likelihood ratio test we only assess gene 
expression and leave the spline for age in the model). The empirical null distributions of this 
analysis are depicted in Figure S13. 
 
For both analyses we observe that the empirical null distribution remains shifted (Δ = 0.448 for 
BRCA and Δ = 1.036 for LIHC) and wider (σ = 1.157 for BRCA and σ = 1.465 for LIHC) than 
the theoretical null, similar to the results obtained in Figure S8, panels E and F. This is in an 
indication that reason (IV) unmeasured confounders is one of the main drivers in the failure of 
the theoretic null.  
 
Initially, we proposed semi-parametric CPH model that studies the association between gene 
expression and survival while correcting for baseline confounders (age for the BRCA dataset, 
age and BMI for the LIHC dataset) with a spline function. As shown above, this model suffers 
from all four issues discussed by Efron (5) regarding the theoretical null distribution of the test 
statistics, jeopardizing correct statistical inference. However, when replacing the spline-based 
LRT test with an LRT test based on a linear and quadratic GE-effect, we no longer observed 
failure of the null due to mathematical assumptions (Figure S10). Nevertheless, the null of this 
Figure S12: Z-scores for the association between gene expression and survival on six permuted BRCA 
(top six panels) an LIHC (bottom six panels) datasets. The blue dashed curves represent the estimated 
empirical null component densities. The green solid curves represent the fitted mixture density, i.e. a mixture 
between the null genes and marker genes (non-null). The data were permuted according to the second 
permutation strategy, as described in Figure S11. To make sure that are conclusions are not driven by one 
specific permutation of the survival data, we repeated the permutation six times for each dataset. For the 
permuted BRCA dataset, the estimated empirical null distribution overlaps almost perfectly with the 
theoretical standard normal distribution (Δ; [-0.09; 0.08] and σ; [0.93; 1.01] for six repeated permutations) 
with only very minor deviations between the empirical null and the observed z-scores. For the LIHC dataset, 
we observe that the empirical null is shifted as compared to the theoretical null (Δ; [-0.08; 0.38] and σ; [0.94; 
1.08]) for the six repeated permutations, with some deviations between the empirical null and the observed z-
scores in the right tail. 
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quadratic CPH model still suffers from unobserved confounders (BRCA and LIHC, Figure S13) 
and from correlation between genes (LIHC, Figure S12). The former, however, could not be 
addressed using the publicly available baseline confounders.  
 
While the empirical null distribution of our final inference procedure did not perfectly fit the 
observed z-scores (Figure S13), we feel that this is the current state-of-the-art workflow to 
analyze the publicly available datasets.  
 
5. Top list of genes associated with survival 
 
There are two major conclusions to our analysis with respect to the discovery of marker genes. 
First, correcting for confounders has an impact on the ranking of the genes with respect to their 
association with survival. This indicates that correcting for confounders in this type of analysis is 
important. This is further emphasized by the fact that, as shown in table S2, two known genes in 
breast cancer (MMP13 and RGL3) are in the top 10 most significantly associated genes only in 
our improved workflow. Second, when the p-values obtained through our final CPH model were 
corrected for (i) deviations from the underlying theoretical null distribution and (ii) multiple 
testing through the lfdr procedure proposed by Efron (6, 7), there was no longer any statistical 
evidence for marker genes that are associated with survival in the BRCA and LIHC case studies 
(Note, that according to the guidelines of Efron, a significance level of 0.2 is used for the lfdr). 
This suggests that the original marker genes that were proposed by Uhlen et al. (1) and that are 
still being communicated via the Human Pathology Atlas web resource can be expected to contain 
a vast number of false positive markers. In tables S1-4, we display the top 10 marker genes that 
are associated with survival in the BRCA and LIHC datasets according to the original (Tables 1 
and 3) and our updated workflow (Tables 2 and 4). The complete tables may be retrieved from 
our companion GitHub page (/dataBRCA and /dataLIHC).
Figure S13:  Z-scores for the association between gene expression and survival on the original BRCA 
(left panel) an LIHC (right panel) datasets when modelling gene expression with a linear and quadratic 
term and correcting for confounders with a spline function. The blue dashed curves represent the 
estimated empirical null component densities. The green solid curves represent the fitted mixture density, 
i.e. a mixture between the null genes and marker genes (non-null). For both analyses we observe that the 
empirical null distribution is shifted (Δ = 0.448 for BRCA and Δ = 1.036 for LIHC) and wider (σ = 1.157 
for BRCA and σ = 1.465 for LIHC) than the theoretical null. This is in an indication that reason (IV) 
unmeasured confounders is one of the main drivers in the failure of the theoretic null. Note that the empirical 



























LRP11 2.49E-04 5.67E-04 1.40E-01 1 2.31E-08 Unfav. 52 1 
ZNF385B 6.23E-05 1.07E-04 1.40E-01 1 4.86E-08 Fav. 9 2 
PGK1 7.49E-06 3.70E-05 1.35E-01 1 7.05E-08 Unfav. 4 3 
CYP24A1 NA NA NA NA 1.19E-07 Fav. NA 4 
PCMT1 6.19E-05 6.04E-04 1.40E-01 1 4.02E-07 Unfav. 56 5 
TP53AIP1 6.14E-06 6,25E-05 1.40E-01 1 4.12E-07 Fav. 5 6 
TFPI2 1.90E-04 4.90E-03 2.08E-01 1 8.33E-07 Fav. 341 7 
FAM173B 6.45E-03 2.35E-02 2.76E-01 1 1.32E-06 Unfav. 1237 8 
IL27RA 3.57E-04 5.25E-03 2.10E-01 1 1.74E-06 Fav. 362 9 
JCHAIN 6.22E-04 4.07E-03 1.96E-01 1 1.81E-06 Fav. 299 10 
Table S1: Effect of our proposed step-by-step improvement of the data analysis workflow on the 
significance levels of the top 10 prognostic genes in breast cancer as communicated by Uhlen et al (1). 
In total, 14.573 genes were assessed. Note, that CYP24A1 was not included in our analysis, as the 
expression level of this gene was below the adopted threshold. Column 1: the p-value for each gene, as 
obtained with the CPH model, is displayed. Column 2: the p-values are obtained again by CPH models, 
that additionally account for the confounder age. Column 3: the p-values of the second column were 
corrected for multiple testing with the FDR method of Benjamin and Hochberg (3). Column 4: the p-
values of the second column were corrected for (i) deviations from the underlying theoretical null 
distribution and (ii) multiple testing through Efron’s lfdr procedure (6,7). Column 5: the p-values as 
communicated in the original publication and the Human Pathology Atlas web resource. Column 6: 
Prognostic type of the gene as determined by the original publication. Can be either favorable or 
unfavorable. Column 7: the rank of the initial top 10 genes based on our workflow (based on the CPH 
age corrected p-values). Note, that the ordering has changed dramatically for some of the genes, which 
is mainly due to our correction for the confounder age. Column 8: the rank of the initial top 10 genes 























RGL3 4.94E-05 2.55E-05 1.35E-01 1 7.35E-04 Fav. 1 698 
SERPINA1 1.94E-04 2.67E-05 1.35E-01 1 1,61E-05 Fav. 2 52 
TTC39C 6.20E-04 3.07E-05 1.35E-01 1 1.48E-04 Fav. 3 264 
PGK1 7.49E-06 3.70E-05 1.35E-01 1 7,05E-08 Unfav. 4 3 
TP53AIP1 6.14E-06 6.25E-05 1.40E-01 1 4,12E-07 Fav. 5 6 
MMP13 1.26E-03 6.30E-05 1.40E-01 1 8.98E-03 Unfav. 6 3042 
QPRT 2.27E-04 6.90E-05 1.40E-01 1 5,10E-05 Unfav. 7 127 
TRAPPC12 1.30E-03 1.06E-04 1.40E-01 1  4,86E-08 Fav. 8 2 
ZNF385B 6.23E-05 1.07E-04 1.40E-01 1 1,80E-05 Fav. 9 57 
PARP3 5.62E-03 1.09E-04 1.40E-01 1 6,39E-05 Fav. 10 144 
 
  
Table S2: Effect of our proposed step-by-step improvement of the data analysis workflow on the 
significance levels of the top 10 prognostic genes in the breast cancer dataset as obtained with our 
workflow. In total, 14.573 genes were assessed. Note, that two known genes in breast cancer (MMP13 
and RGL3) are in the top 10 most significantly associated genes only in our improved workflow. Column 
1: the p-value for each gene, as obtained with the CPH model, is displayed. Column 2: the p-values are 
obtained again by CPH models, that additionally account for the confounder age. Column 3: the p-values 
of the second column were corrected for multiple testing with the FDR method of Benjamin and 
Hochberg (3). Column 4: the p-values of the second column were corrected for (i) deviations from the 
underlying theoretical null distribution and (ii) multiple testing through Efron’s lfdr procedure (6,7). 
Column 5: the p-values as communicated in the original publication and the Human Pathology Atlas 
web resource. Column 6: Prognostic type of the gene as determined by the original publication. Can be 
either favorable or unfavorable. Column 7: the rank of the initial top 10 genes based on our workflow 
(based on the CPH age corrected p-values). Note, that the ordering has changed dramatically for some of 
the genes, which is mainly due to our correction for the confounder age. Column 8: the rank of the initial 






















SFPQ 1.06E-06 1.25E-07 8.63E-05 1 7.91E-13 Unfav. 18 1 
G6PD 2.83E-07 3.21E-08 4.10E-05 1 9.45E-13 Unfav. 10 2 
KIF20A 8.02E-07 7.17E-08 6.39E-05 1 2.14E-12 Unfav. 15 3 
KDM1A 3.68E-07 9.66E-09 3.22E-05 1 4.47E-12 Unfav. 3 4 
TRMT6 2.09E-08 7.15E-09 3.22E-05 1 4.70E-12 Unfav. 1 5 
PSMD1 1.61E-06 1.61E-07 9.40E-05 1 8.63E-12 Unfav. 22 6 
GTPBP4 1.28E-06 2.07E-06 3.38E-04 1 8.85E-12 Unfav. 81 7 
CCT4 2.14E-08 1.75E-08 3.34E-05 1 9.37E-12 Unfav. 7 8 
CAD 2.27E-06 3.20E-07 1.22E-04 1 1.72E-11 Unfav. 35 9 
CBX2 6.13E-08 8.77E-08 7.34E-05 1 2.25E-11 Unfav. 16 10 
 
  
Table S3: Effect of our proposed step-by-step improvement of the data analysis workflow on the 
significance levels of the top 10 prognostic genes in liver cancer as communicated by Uhlen et al (1). In 
total, 13.376 genes were assessed. Column 1: the p-value for each gene, as obtained with the CPH model, 
is displayed. Column 2: the p-values are obtained again by CPH models, that additionally account for 
confounders age and BMI. Column 3: the p-values of the second column were corrected for multiple testing 
with the FDR method of Benjamin and Hochberg (3). Column 4: the p-values of the second column were 
corrected for (i) deviations from the underlying theoretical null distribution and (ii) multiple testing through 
Efron’s lfdr procedure (6,7). Column 5: the p-values as communicated in the original publication and the 
Human Pathology Atlas web resource. Column 6: Prognostic type of the gene as determined by the original 
publication. Can be either favorable or unfavorable. Column 7: the rank of the initial top 10 genes based 
on our workflow (based on the CPH age and BMI corrected p-values). Column 8: the rank of the initial top 























TRMT6 2.09E-08 7.15E-09 3.22E-05 1 2,30E-10 Unfav. 1 5 
PSRC1 1.86E-07 9.49E-09 3.22E-05 1 2,14E-12 Unfav. 2 31 
KDM1A 3.68E-07 9.66E-09 3.22E-05 1 4,70E-12 Unfav. 3 4 
KPNA2 7.88E-07 9.86E-09 3.22E-05 1 2,12E-10 Unfav. 4 18 
HDAC2 9.02E-08 1.21E-08 3.22E-05 1 7,44E-08 Unfav. 5 22 
CCDC77 1.44E-06 1.72E-08 3.34E-05 1 5,39E-10 Unfav. 6 373 
CCT4 2.14E-08 1.75E-08 3.34E-05 1 6,45E-10 Unfav. 7 8 
UTP11L 3.66E-08 2.12E-08 3.54E-05 1 4,30E-11 Unfav. 8 163 
HILPDA 3.98E-07 2.74E-08 4.07E-05 1 1,36E-09 Unfav. 9 12 
G6PD 2.83E-07 3.21E-08 4.10E-05 1 9,19E-09 Unfav. 10 2 
Table S4: Effect of our proposed step-by-step improvement of the data analysis workflow on the 
significance levels of the top 10 prognostic genes in the liver cancer dataset as obtained with our 
workflow. In total, 13.376 genes were assessed. Column 1: the p-value for each gene, as obtained with 
the CPH model, is displayed. Column 2: the p-values are obtained again by CPH models, that 
additionally account for confounders age and BMI. Column 3: the p-values of the second column were 
corrected for multiple testing with the FDR method of Benjamin and Hochberg (3). Column 4: the p-
values of the second column were corrected for (i) deviations from the underlying theoretical null 
distribution and (ii) multiple testing through Efron’s lfdr procedure (6,7). Column 5: the p-values as 
communicated in the original publication and the Human Pathology Atlas web resource. Column 6: 
Prognostic type of the gene as determined by the original publication. Can be either favorable or 
unfavorable. Column 7: the rank of the initial top 10 genes based on our workflow (based on the CPH 
age and BMI corrected p-values). Column 8: the rank of the initial top 10 genes based on the original 
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